<DOC>
	<DOC>NCT01966003</DOC>
	<brief_summary>The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.</brief_summary>
	<brief_title>Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed nonsquamous nonsmall cell lung cancer Subjects must be initiating firstline carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 cycles of chemotherapy Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 Small cell lung cancer (SCLC) or mixed SCLC and NSCLC Central nervous system (CNS) metastases Malignancy other than NSCLC Palliative radiotherapy for bone lesions inside the thorax Prior radiotherapy of bone marrow Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) Life expectancy &lt; 6 months Woman of childbearing potential who is pregnant or is breast feeding or who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products Other inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>